Development of Emerin mRNA Lipid Nanoparticles to Rescue Myogenic Differentiation
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26167774 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Nicholas Marano und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ 08103, USA. Hauptthemen laut MEDLINE: Cell Differentiation, RNA, Messenger, Membrane Proteins, Nanoparticles. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAMS NIH HHS, National Institute of Arthritis and Musculoskeletal and Skin Diseases.
Abstract (Originalsprache)
Emery–Dreifuss muscular dystrophy 1 (EDMD1) arises from mutations in EMD. Most EDMD1 patients lack detectable emerin expression. They experience symptoms such as skeletal muscle wasting, joint contractures, and cardiac conduction defects. Currently, physicians rely on treating patient symptoms without addressing the underlying cause—lack of functional emerin protein. Thus, there is a need for therapeutic approaches that restore emerin protein expression to improve patient outcomes. One way would be to deliver emerin mRNA or protein directly to affected tissues to restore tissue homeostasis. Here, we evaluated the utility of lipid nanoparticles (LNPs) to deliver emerin mRNA to diseased cells. LNPs have been studied for decades and have recently been used clinically for vaccination and treatment of a myriad of diseases. Here, we show that the treatment of emerin-null myogenic progenitors with LNPs encapsulating emerin mRNA causes robust emerin protein expression that persists for at least 4 days. The treatment of differentiating emerin-null myogenic progenitors with 2.5 pg/cell emerin LNPs significantly improved their differentiation. The toxicity profiling of emerin mRNA LNP (EMD-LNP) dosing shows little toxicity at the effective dose. These data support the potential use of EMD-LNPs as a viable treatment option and establishes its utility for studying EDMD pathology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ 08103, USA.
- Rowan-Virtua School of Translational Biomedical Engineering and Sciences, Rowan University, Stratford, NJ 08084, USA.
- Department of Biomedical Engineering, Henry M. Rowan College of Engineering, Rowan University, Glassboro, NJ 08028, USA.
ORCID-Profile: Nicholas Marano, Liza Elif Guner, James M Holaska
Förderung
- NIAMS NIH HHS
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
Zitieren
APA
Marano, N., Guner, L. E., Riley, R. S., & Holaska, J. M. (2025). Development of Emerin mRNA Lipid Nanoparticles to Rescue Myogenic Differentiation. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26167774
Vancouver
Marano N, Guner LE, Riley RS, Holaska JM. Development of Emerin mRNA Lipid Nanoparticles to Rescue Myogenic Differentiation. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26167774
BibTeX
@article{Marano2025,
author = {Marano, Nicholas and Guner, Liza Elif and Riley, Rachel S and Holaska, James M},
title = {Development of Emerin mRNA Lipid Nanoparticles to Rescue Myogenic Differentiation},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26167774}
}
EUVIMED